Neuropsychiatric DisordersFIT-IRMNCT07453108
Reference Measurements of the Neuronal Integration Window and Anatomical and Functional MRI (Magnetic Resonance Imaging)
A study testing MRI (Magnetic Resonance Imaging) and TMS (Transcranial Magnetic Stimulation) in people with Neuropsychiatric Disorders, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Our studies on MRI (Magnetic resonance imaging) biomarkers in neuropsychiatric disorders rely on reference data from control subjects which are dependent from our scanner. Due to the upcoming replacement of our MR scanner, the investigators need to 'recalibrate' our current database by acquiring the same data on both… Read more about this study
- Who is it for?
- Ages 18 to 86 yearsHealthy volunteers can take part
- Conditions the study is for
- Neuropsychiatric Disorders
- What is being tested?
- MRI (Magnetic Resonance Imaging) and TMS (Transcranial Magnetic Stimulation)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteFrance
- Study dates
- 17 May 2023to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 86 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Men or women aged 18 to 86 inclusive;
- Affiliated to a social health insurance scheme
- Able to understand the objectives and risks of the research and to give dated and signed informed consent;
- B2 or above level of French language according to the European Framework of Reference for Languages;
- No personal or family psychiatric history of endogenous psychosis, including substance abuse (excluding moderate tobacco, alcohol and caffeine use);
- No chronic pathology requiring treatment (mainly diabetes, hypertension, hyperlipidemia or cholesterolemia);
- Matched on age, gender and education level of the patients included in our different studies
- Woman of childbearing age: negative urine pregnancy test at the inclusion visit and effective contraception throughout the study (intrauterine device, sterilisation, oestrogen or progestin per os, injectable or as an implant or ring).
Who cannot join
- Contraindication to MRI or rTMS: presence of a non-removable ferromagnetic foreign body, prosthesis, pacemaker, medication delivered by an implanted pump, vascular clip or stent, heart valve or ventricular bypass, epilepsy;
- History that may affect brain anatomy or be related to an abnormality (neurosurgery, epilepsy, stroke, head injury with loss of consciousness for more than 15 minutes and mental retardation - Intelligence Quotient (IQ) < 70 on the fNART);
- History of potentially affecting brain function (general anaesthesia or Electroconvulsive Therapy (ECT) < 3 months prior to inclusion);
- Breastfeeding women ;
- Pregnant women ;
- Serious or unstabilised somatic pathology ;
Show all 11Show fewer
- Chronic intake of a treatment related to an ongoing disease;
- Deprived of liberty, in forced care or under legal protection ;
- Under guardianship or curatorship ;
- Emergency or life-threatening situation) ;
- Exclusion period (determined by a previous or current study).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Reference Measurements of the Neuronal Integration Window and Anatomical and Functional MRI
Our studies on MRI (Magnetic resonance imaging) biomarkers in neuropsychiatric disorders rely on reference data from control subjects which are dependent from our scanner. Due to the upcoming replacement of our MR scanner, the investigators need to 'recalibrate' our current database by acquiring the same data on both the old and the new device from a small group of controls (n = 36 to 40). This will be combined with measures of cortical excitability using robotized TMS (transcranial magnetic stimulation) that will be combined to MRI biomarkers in forthcoming studies.
Therefore, the primary objective of this biomedical trial is to collect MRI and physiological measurements in normal subjects whose characteristics match to our study populations.
Read the detailed description
An inclusion period of 4 months will allow for the inclusion of the necessary subjects.
Controls will be recruited through mailings, classified ads and/or posters, adapting age, gender and education criteria as the investigators go along to match investigators's target populations.
Making contact and appointments: During the telephone contact with the subject, the investigators provide the initial information concerning the objectives, the course and the constraints of the study. An appointment will be made after checking that the main eligibility criteria have been met.
Information and selection visit (min. 24 hours before V0): This visit can be carried out by web-conference or on one of the technical platforms (iCube laboratory).
After checking that the participant meets all the eligibility criteria, the investigator will repeat the information about the protocol and its constraints and answer the subject's questions. The patient will be offered a reflection period of at least 24 hours. If the patient accepts, an appointment will be made for the inclusion visit.
Inclusion visit (V0) - MRI -1: This visit will take place on the "3Tesla MRI" technical platform. After answering any further questions, the investigator will obtain the patient's free, informed and written consent.
The investigator then connects to Hédonix®, a dedicated web application with a personal login and password. He then fills in the entry form: surname, first name, date of birth, e-mail, telephone number, address. Hédonix® automatically generates an entry identification number and a password for the subject.
The investigator uploads the scanned version of the signed consent forms to Hedonix® and collects the following information Socio-demographic data: gender, age, level of education, age of learning French, level of language proficiency, professional activity, marital status, lifestyle, parents' socio-economic level. Vascular risk factors: habitus (cigarettes, alcohol, coffee etc.), blood pressure, weight, water and fat content (impedance measurement), height, waist circumference, capillary blood sugar.
Personal medical history (including psychiatric, neurological, substance abuse, immune disorders), incidents during pregnancy (weight loss, infection), treatment, stress, term, season, delivery complication). Family history with a family tree up to the 3de degree of relatedness if possible (cousins/great grandparents), collecting as much information as possible about possible psychiatric, neurological and systemic diseases Hetero-questionnaires and cognitive tests: Psychometrics (fNART= french National Adult Reading Test). Attentional testing (TAP = Tests of Attentional Performance, continuous performance test , semantic priming ) Self-questionnaires: The subject logs in to Hedonix® with his/her login and password to complete the following self- questionnaires.
'Characterisation and screening: MRI and TMS* contraindication checklist (double-check - possible study exit if screened at this stage), Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) level 1 screening instrument (D1-DS= screening for the main psychiatric diseases), manual dominance (EHI= Edinburgh Handedness Inventory), sedation (ESS= Epworth Sleepiness Scale), screening for a bipolarity (MDQ= Mood Disorder Questionnaire), ruminations (mini-CERTS= Mini Cambridge-Exeter Repetitive Thought Scale), psychometrics (Mill-Hill, EQ= Empathy Quotient), personality traits (BFI= Big Five Inventory, TIPI=Temperament assessment, chronotype), stress exposure (past Acquired Brain Injury (ABI) or recent Life Stressor Condition (LSC)).
Current symptoms (assessed over the previous month): apathy (AES-S=Apathy Evaluation Scale ), tiredness (MFI =Multidimensional Fatigue Inventory ), physical activity (RGQ= Ricci and Gagnon Questionnaire), depression (IDS30-SR= Inventory of Depressive Symptomatology (subject rated)), anhedonia (SHAPS= Snaith-Hamilton Pleasure Scale, TEPS= Temporal Experience of Pleasure Scale).
For normative purposes: ECJM (Moral Choice and Judgment Evaluation) IRM-1 : On the same day, the MRI-1 will be performed on the 3T Vério Siemens MRI of the iCube laboratory's iBiSA-labelled (Infrastructures in Biology, Health, and Agronomy (a French national label for high-level scientific platforms) IRIS platform (Research Infrastructure for Imaging and Health, a French platform for advanced biomedical imaging).
Visit V1 (week1 to week 8) - MRI - 2: MRI 2 will be performed on the 3T Vério Siemens MRI of the IRIS platform of the iCube laboratory.
Visit V2 (w2 to w12) - Mapping and excitability of motor cortex: Physiological measurements will be carried out at CEMNIS (Centre de neuro-Modulation Non-Invasive de Strasbourg), a "robotic rTMS" (repetitive Transcranial Magnetic Stimulation) platform.
The subject will begin by performing psychophysical tests measuring the window of perception of simultaneity in visual, auditory and bimodal modalities.
Then the mapping and measurement of excitability, inhibition and "temporal integration window" parameters will be performed using our robotic TMS device under neuro-navigation.
Visit V3 (w20 to w28) - MRI-1: This visit will take place on the "3T MRI" technical platform of the IRIS platform (iCube laboratory). The subject logs in to Hedonix® with his/her login and password to fill in the following self- questionnaires concerning current symptoms (assessed over the previous month): apathy (AES-S), tiredness (MFI), physical activity (RGQ), depression (IDS30-SR), anhedonia (SHAPS, TEPS).
The MRI-1 will be performed on the new 3T Vida Siemens MRI of the IRIS platform of the iCube laboratory. The sequences will have the same purpose and use the same parameters as the MRI-1. The functional novelty will be the ability to record EEG (electroencephalogram) activity at the same time, which will allow the effects of changes in alertness to be assessed, something that could not be coupled with pre-therapy MRI on our previous MRI without a change of antenna
Visit V4 (w21 to w32) - MRI-2: This visit should be at least one week later than the previous one. MRI-2 (n°4) will be performed on the new 3T Vida Siemens MRI and the dedicated EEG of the IRIS platform of the iCube laboratory. The sequences will have the same purpose and will use the same parameters as the MRI-2. Most of the sequences are functional, but the acceleration of acquisition times will not result in a significant reduction of the total examination time as the latter will be used to increase the number of volumes acquired.
- Conditions
- Neuropsychiatric Disorders
- Being tested
- MRI (Magnetic Resonance Imaging), TMS (Transcranial Magnetic Stimulation)
- Keywords
- MRI (Magnetic Resonance Imaging System), TMS (transcranial magnetic stimulation)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRI (Magnetic Resonance Imaging)Other
2 MRI sessions on 3 Tesla Vério Siemens scanner at V1, separated by minimum one week
Anatomical and functional measures:
- 3 ASL-fMRI with ET = 9.7 ms, 3 ASL-fMRI with ET = 21 ms during various tasks.
- Multiparametric quantitative measures (NODDI, R1, R2, R2*, magnetic susceptibility, macromolecular proton fraction).
- 3DT1 and 3D FLAIR.
TMS (Transcranial Magnetic Stimulation)Other
1 session at visit V2. Intracortical inhibition, neuronal integration and window of simultaneity Mapping of passive and active motor evoked potential MEP using dedicated robotic device under the control of neuronavigation. + cortical and trans-cortical silence period
MRI (Magnetic Resonance Imaging)Other
2 MRI sessions on 3 Tesla Vida scanner at V3, separated by minimum one week. 2 MRI sessions on "new" MR-scanner
Anatomical and functional measures:
- 3 ASL-fMRI with ET = 9.7 ms, 3 ASL-fMRI with ET = 21 ms during various tasks.
- Multiparametric quantitative measures (NODDI, R1, R2, R2*, magnetic susceptibility, macromolecular proton fraction).
- 3DT1 and 3D FLAIR.
| Study group | Role | What they receive |
|---|---|---|
| Healthy subjects | Other | Healthy subjects Receives: Other: MRI (Magnetic Resonance Imaging); Other: TMS (Transcranial Magnetic Stimulation) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recalibration of MRI database
Number of subjects for whom complete and sufficient high-quality data have been collected
Measured: From enrollment to the end of participation at 39.5 months maximum
Physiological parameters
Reproduction of results for motor mapping of the motor evoked potential (MEP) - both passive and active - and of the silent period, as well as estimation of the distribution functions for the various measurements.
Measured: From enrollment to the end of participation at 39.5 months maximum
Secondary outcomes (1)
Incidence of adverse events (AEs) during the various procedures
Incidence of adverse events (AEs) during the various procedures
Measured: From enrollment to the end of participation at 39.5 months maximum
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2026
- Study start17 May 2023
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuropsychiatric DisordersStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Healthy subjects: maximum of 40 inclusions to have at least 36 usable results.
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jack FOUCHER, Principal investigator, CEntre de neuroModulation Non-Invasive de Strasbourg (CEMNIS)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07453108
- Sponsor's protocol ID
- 8890
- Acronym
- FIT-IRM
- Status last verified
- Feb 2026
- First submitted
- 3 Apr 2023
- Last updated
- 5 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reference Measurements of the Neuronal Integration Window and Anatomical and Functional MRI
- ClinicalTrials.gov ID
- NCT07453108
- Acronym / sponsor ID
- FIT-IRM / 8890
- Conditions
- Neuropsychiatric Disorders
- Keywords
- MRI (Magnetic Resonance Imaging System), TMS (transcranial magnetic stimulation)
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 17 May 2023 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 5 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our studies on MRI (Magnetic resonance imaging) biomarkers in neuropsychiatric disorders rely on reference data from control subjects which are dependent from our scanner. Due to the upcoming replacement of our MR scanner, the investigators need to 'recalibrate' our current database by acquiring the same data on both the old and the new device from a small group of controls (n = 36 to 40). This will be combined with measures of cortical excitability using robotized TMS (transcranial magnetic stimulation) that will be combined to MRI biomarkers in forthcoming studies.
Therefore, the primary objective of this biomedical trial is to collect MRI and physiological measurements in normal subjects whose characteristics match to our study populations.
Detailed description
An inclusion period of 4 months will allow for the inclusion of the necessary subjects.
Controls will be recruited through mailings, classified ads and/or posters, adapting age, gender and education criteria as the investigators go along to match investigators's target populations.
Making contact and appointments: During the telephone contact with the subject, the investigators provide the initial information concerning the objectives, the course and the constraints of the study. An appointment will be made after checking that the main eligibility criteria have been met.
Information and selection visit (min. 24 hours before V0): This visit can be carried out by web-conference or on one of the technical platforms (iCube laboratory).
After checking that the participant meets all the eligibility criteria, the investigator will repeat the information about the protocol and its constraints and answer the subject's questions. The patient will be offered a reflection period of at least 24 hours. If the patient accepts, an appointment will be made for the inclusion visit.
Inclusion visit (V0) - MRI -1: This visit will take place on the "3Tesla MRI" technical platform. After answering any further questions, the investigator will obtain the patient's free, informed and written consent.
The investigator then connects to Hédonix®, a dedicated web application with a personal login and password. He then fills in the entry form: surname, first name, date of birth, e-mail, telephone number, address. Hédonix® automatically generates an entry identification number and a password for the subject.
The investigator uploads the scanned version of the signed consent forms to Hedonix® and collects the following information Socio-demographic data: gender, age, level of education, age of learning French, level of language proficiency, professional activity, marital status, lifestyle, parents' socio-economic level. Vascular risk factors: habitus (cigarettes, alcohol, coffee etc.), blood pressure, weight, water and fat content (impedance measurement), height, waist circumference, capillary blood sugar.
Personal medical history (including psychiatric, neurological, substance abuse, immune disorders), incidents during pregnancy (weight loss, infection), treatment, stress, term, season, delivery complication). Family history with a family tree up to the 3de degree of relatedness if possible (cousins/great grandparents), collecting as much information as possible about possible psychiatric, neurological and systemic diseases Hetero-questionnaires and cognitive tests: Psychometrics (fNART= french National Adult Reading Test). Attentional testing (TAP = Tests of Attentional Performance, continuous performance test , semantic priming ) Self-questionnaires: The subject logs in to Hedonix® with his/her login and password to complete the following self- questionnaires.
'Characterisation and screening: MRI and TMS* contraindication checklist (double-check - possible study exit if screened at this stage), Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) level 1 screening instrument (D1-DS= screening for the main psychiatric diseases), manual dominance (EHI= Edinburgh Handedness Inventory), sedation (ESS= Epworth Sleepiness Scale), screening for a bipolarity (MDQ= Mood Disorder Questionnaire), ruminations (mini-CERTS= Mini Cambridge-Exeter Repetitive Thought Scale), psychometrics (Mill-Hill, EQ= Empathy Quotient), personality traits (BFI= Big Five Inventory, TIPI=Temperament assessment, chronotype), stress exposure (past Acquired Brain Injury (ABI) or recent Life Stressor Condition (LSC)).
Current symptoms (assessed over the previous month): apathy (AES-S=Apathy Evaluation Scale ), tiredness (MFI =Multidimensional Fatigue Inventory ), physical activity (RGQ= Ricci and Gagnon Questionnaire), depression (IDS30-SR= Inventory of Depressive Symptomatology (subject rated)), anhedonia (SHAPS= Snaith-Hamilton Pleasure Scale, TEPS= Temporal Experience of Pleasure Scale).
For normative purposes: ECJM (Moral Choice and Judgment Evaluation) IRM-1 : On the same day, the MRI-1 will be performed on the 3T Vério Siemens MRI of the iCube laboratory's iBiSA-labelled (Infrastructures in Biology, Health, and Agronomy (a French national label for high-level scientific platforms) IRIS platform (Research Infrastructure for Imaging and Health, a French platform for advanced biomedical imaging).
Visit V1 (week1 to week 8) - MRI - 2: MRI 2 will be performed on the 3T Vério Siemens MRI of the IRIS platform of the iCube laboratory.
Visit V2 (w2 to w12) - Mapping and excitability of motor cortex: Physiological measurements will be carried out at CEMNIS (Centre de neuro-Modulation Non-Invasive de Strasbourg), a "robotic rTMS" (repetitive Transcranial Magnetic Stimulation) platform.
The subject will begin by performing psychophysical tests measuring the window of perception of simultaneity in visual, auditory and bimodal modalities.
Then the mapping and measurement of excitability, inhibition and "temporal integration window" parameters will be performed using our robotic TMS device under neuro-navigation.
Visit V3 (w20 to w28) - MRI-1: This visit will take place on the "3T MRI" technical platform of the IRIS platform (iCube laboratory). The subject logs in to Hedonix® with his/her login and password to fill in the following self- questionnaires concerning current symptoms (assessed over the previous month): apathy (AES-S), tiredness (MFI), physical activity (RGQ), depression (IDS30-SR), anhedonia (SHAPS, TEPS).
The MRI-1 will be performed on the new 3T Vida Siemens MRI of the IRIS platform of the iCube laboratory. The sequences will have the same purpose and use the same parameters as the MRI-1. The functional novelty will be the ability to record EEG (electroencephalogram) activity at the same time, which will allow the effects of changes in alertness to be assessed, something that could not be coupled with pre-therapy MRI on our previous MRI without a change of antenna
Visit V4 (w21 to w32) - MRI-2: This visit should be at least one week later than the previous one. MRI-2 (n°4) will be performed on the new 3T Vida Siemens MRI and the dedicated EEG of the IRIS platform of the iCube laboratory. The sequences will have the same purpose and will use the same parameters as the MRI-2. Most of the sequences are functional, but the acceleration of acquisition times will not result in a significant reduction of the total examination time as the latter will be used to increase the number of volumes acquired.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Healthy subjects: maximum of 40 inclusions to have at least 36 usable results.
| Arm | Type | Receives |
|---|---|---|
| Healthy subjects | Other | Other: MRI (Magnetic Resonance Imaging), Other: TMS (Transcranial Magnetic Stimulation)Healthy subjects |
Who may qualify
- Ages
- 18 to 86 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Men or women aged 18 to 86 inclusive;
- Affiliated to a social health insurance scheme
- Able to understand the objectives and risks of the research and to give dated and signed informed consent;
- B2 or above level of French language according to the European Framework of Reference for Languages;
- No personal or family psychiatric history of endogenous psychosis, including substance abuse (excluding moderate tobacco, alcohol and caffeine use);
Key exclusion criteria (11 listed)
- Contraindication to MRI or rTMS: presence of a non-removable ferromagnetic foreign body, prosthesis, pacemaker, medication delivered by an implanted pump, vascular clip or stent, heart valve or ventricular bypass, epilepsy;
- History that may affect brain anatomy or be related to an abnormality (neurosurgery, epilepsy, stroke, head injury with loss of consciousness for more than 15 minutes and mental retardation - Intelligence Quotient (IQ) < 70 on the fNART);
- History of potentially affecting brain function (general anaesthesia or Electroconvulsive Therapy (ECT) < 3 months prior to inclusion);
- Breastfeeding women ;
- Pregnant women ;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRI (Magnetic Resonance Imaging)2 MRI sessions on 3 Tesla Vério Siemens scanner at V1, separated by minimum one week Anatomical and functional measures: * 3 ASL-fMRI with ET = 9.7 ms, 3 ASL-fMRI with ET = 21 ms during various tasks. * Multiparametric quantitative measures (NODDI, R1, R2, R2*, magnetic susceptibility, macromolecular proton fraction). * 3DT1 and 3D FLAIR. | Other | Healthy subjects |
| TMS (Transcranial Magnetic Stimulation)1 session at visit V2. Intracortical inhibition, neuronal integration and window of simultaneity Mapping of passive and active motor evoked potential MEP using dedicated robotic device under the control of neuronavigation. + cortical and trans-cortical silence period | Other | Healthy subjects |
| MRI (Magnetic Resonance Imaging)2 MRI sessions on 3 Tesla Vida scanner at V3, separated by minimum one week. 2 MRI sessions on "new" MR-scanner Anatomical and functional measures: * 3 ASL-fMRI with ET = 9.7 ms, 3 ASL-fMRI with ET = 21 ms during various tasks. * Multiparametric quantitative measures (NODDI, R1, R2, R2*, magnetic susceptibility, macromolecular proton fraction). * 3DT1 and 3D FLAIR. | Other | Healthy subjects |
Primary outcome
Recalibration of MRI database
Time frame: From enrollment to the end of participation at 39.5 months maximum
Number of subjects for whom complete and sufficient high-quality data have been collected
Physiological parameters
Time frame: From enrollment to the end of participation at 39.5 months maximum
Reproduction of results for motor mapping of the motor evoked potential (MEP) - both passive and active - and of the silent period, as well as estimation of the distribution functions for the various measurements.
1 secondary outcome
Incidence of adverse events (AEs) during the various procedures
Time frame: From enrollment to the end of participation at 39.5 months maximum
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Neuropsychiatric Disorders
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
Active, not recruitingObservational study
Electrophysiologic Sleep Phenotyping and Sleep-Dependent Neuro-maturation in Clinical and Healthy Pediatric Populations
Healthy Children, Children With Neurodevelopmental Disorders
RecruitingObservational study
TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age
Cystic Fibrosis (CF)
RecruitingObservational study
A Longitudinal Natural History Study of Immune Biomarkers in Neuropsychiatric Illness
Neuropsychiatric Disorders, Neuroinflammatory Disorders
RecruitingObservational study
Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus Erythematosus
SLE - Systemic Lupus Erythematosus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jack FOUCHER principal investigator
CEntre de neuroModulation Non-Invasive de Strasbourg (CEMNIS)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MRI (Magnetic Resonance Imaging) and TMS (Transcranial Magnetic Stimulation) in people with Neuropsychiatric Disorders, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recalibration of MRI database (time frame: From enrollment to the end of participation at 39.5 months maximum). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.